Xianjun Yu

559 total citations
20 papers, 454 citations indexed

About

Xianjun Yu is a scholar working on Molecular Biology, Complementary and alternative medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Xianjun Yu has authored 20 papers receiving a total of 454 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 8 papers in Complementary and alternative medicine and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Xianjun Yu's work include Natural Compounds in Disease Treatment (8 papers), Cancer Mechanisms and Therapy (4 papers) and Natural product bioactivities and synthesis (4 papers). Xianjun Yu is often cited by papers focused on Natural Compounds in Disease Treatment (8 papers), Cancer Mechanisms and Therapy (4 papers) and Natural product bioactivities and synthesis (4 papers). Xianjun Yu collaborates with scholars based in China and Hong Kong. Xianjun Yu's co-authors include Qun Zhao, Yun Bi, Yingxiang Liu, Jing Zhong, Yan Tan, Yongqiang Liu, Jingxuan Zhang, Jian Guo, Mengting Yu and Xuzhi Ruan and has published in prestigious journals such as Nano Letters, International Journal of Molecular Sciences and Molecules.

In The Last Decade

Xianjun Yu

19 papers receiving 447 citations

Peers

Countries citing papers authored by Xianjun Yu

Since Specialization

Citations

This map shows the geographic impact of Xianjun Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xianjun Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xianjun Yu more than expected).

Fields of papers citing papers by Xianjun Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xianjun Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xianjun Yu. The network helps show where Xianjun Yu may publish in the future.

Co-authorship network of co-authors of Xianjun Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Xianjun Yu. A scholar is included among the top collaborators of Xianjun Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xianjun Yu. Xianjun Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pristimerin induces Noxa-dependent apoptosis by activating the FoxO3a pathway in esophageal squamous cell carcinoma 2025 ·Chinese Journal of Natural Medicines ·(unknown), (unknown), Jingyi Wu, (unknown), Qingyu Yang, (unknown), Xiaohui Hu, (unknown), Xianjun Yu, Qun Zhao	0
2	CXCL13 suppresses liver regeneration through the negative regulation of HGF signaling 2025 ·Cell Death and Disease ·(unknown), Jingyi Wu, (unknown), (unknown), Liwei Fu, Jinglin Chen, Lian Li, (unknown), Tingting Li, Shu Jin, (unknown), Xianjun Yu	1
3	Gambogenic acid induces apoptosis via upregulation of Noxa in oral squamous cell carcinoma 2024 ·Chinese Journal of Natural Medicines ·(unknown), (unknown), (unknown), Jian Guo, (unknown), Xiaohui Hu, Quan‐Bin Han, (unknown), Xianjun Yu	2
4	10,11-Dehydrocurvularin attenuates inflammation by suppressing NLRP3 inflammasome activation 2023 ·Chinese Journal of Natural Medicines ·Qun Zhao, (unknown), (unknown), (unknown), (unknown), Jian Guo, (unknown), Guang‐Biao Zhou, Xianjun Yu	3
5	Pristimerin induces apoptosis and tumor inhibition of oral squamous cell carcinoma through activating ROS-dependent ER stress/Noxa pathway 2021 ·Phytomedicine ·Qun Zhao, (unknown), (unknown), Yun Bi, Jian Guo, (unknown), (unknown), He Li, Xianjun Yu	12
6	CXCL13 promotes intestinal tumorigenesis through the activation of epithelial AKT signaling 2021 ·Cancer Letters ·Qun Zhao, Jian Guo, Guizhen Wang, Yun Bi, (unknown), (unknown), Shu Jin, Lian Li, Yang Guo, (unknown), Xu Dong Zhang, Yan Tan, Guang‐Biao Zhou, Xianjun Yu	15
7	Review of 10,11-Dehydrocurvularin: Synthesis, Structural Diversity,Bioactivities and Mechanisms 2021 ·Mini-Reviews in Medicinal Chemistry ·(unknown), Yiqing Zhou, Zhiyong Guo, Xianjun Yu, Zhangshuang Deng	3
8	A Nanodrug Coated with Membrane from Brain Microvascular Endothelial Cells Protects against Experimental Cerebral Malaria 2021 ·Nano Letters ·Wei Wei, Weijia Cheng, Wenhao Dai, Feng Lu, Yaru Cheng, Tingting Jiang, (unknown), Yiting Xie, Jiahui Xu, Qun Zhao, Xianjun Yu, Yi Yin, Jian Li, Haifeng Dong	23
9	Phytochemical library screening reveals betulinic acid as a novel Skp2‐SCF E3 ligase inhibitor in non–small cell lung cancer 2021 ·Cancer Science ·Dan‐Hua He, Yufei Chen, (unknown), (unknown), Ming Hong, Xianjun Yu, (unknown), (unknown), Siyi Li, Qi Wang, Yongzhi Lu, Yongqiang Liu	21
10	Effect of pristimerin on apoptosis through activation of ROS/ endoplasmic reticulum (ER) stress-mediated noxa in colorectal cancer 2020 ·Phytomedicine ·Qun Zhao, Yun Bi, Jian Guo, Yingxiang Liu, Jing Zhong, Yongqiang Liu, (unknown), Yang Guo, Yan Tan, Xianjun Yu	33
11	Pristimerin protects against inflammation and metabolic disorder in mice through inhibition of NLRP3 inflammasome activation 2020 ·Acta Pharmacologica Sinica ·Qun Zhao, Yun Bi, Jian Guo, Yingxiang Liu, Jing Zhong, (unknown), Yan Tan, Xianjun Yu	24
12	Gambogenic acid induces Noxa-mediated apoptosis in colorectal cancer through ROS-dependent activation of IRE1α/JNK 2020 ·Phytomedicine ·Qun Zhao, Jing Zhong, Yun Bi, Yongqiang Liu, Yingxiang Liu, Jian Guo, (unknown), Yan Tan, Xianjun Yu	39
13	10,11-dehydrocurvularin exerts antitumor effect against human breast cancer by suppressing STAT3 activation 2020 ·Acta Pharmacologica Sinica ·Qun Zhao, Yun Bi, Jing Zhong, (unknown), Jian Guo, Yingxiang Liu, (unknown), Yan Tan, Zhangshuang Deng, Xianjun Yu	19
14	Pristimerin induces apoptosis and autophagy via activation of ROS/ASK1/JNK pathway in human breast cancer in vitro and in vivo 2019 ·Cell Death Discovery ·Qun Zhao, Yingxiang Liu, Jing Zhong, Yun Bi, Yongqiang Liu, (unknown), Xiang Li, (unknown), Mengting Yu, Xianjun Yu	76
15	Pristimerin suppresses colorectal cancer through inhibiting inflammatory responses and Wnt/β-catenin signaling 2019 ·Toxicology and Applied Pharmacology ·Qun Zhao, Yun Bi, Jing Zhong, (unknown), Yingxiang Liu, (unknown), Mengting Yu, Yan Tan, Qiufang Zhang, Xianjun Yu	39
16	Pristimerin Induces Autophagy‐Mediated Cell Death in K562 Cells through the ROS/JNK Signaling Pathway 2019 ·Chemistry & Biodiversity ·Yingxiang Liu, (unknown), Xiang Li, Jing Zhong, Yun Bi, (unknown), Qun Zhao, Xianjun Yu	21
17	Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation 2017 ·Oncotarget ·Xianjun Yu, Qun Zhao, Xixi Zhang, Haiwei Zhang, Yongbo Liu, Xiaoxia Wu, Ming Li, Xiaoming Li, Jingxuan Zhang, Xuzhi Ruan, Haibing Zhang	50
18	Gambogenic acid induces proteasomal degradation of CIP2A and sensitizes hepatocellular carcinoma to anticancer agents 2016 ·Oncology Reports ·Xianjun Yu, Qun Zhao, Xuanbin Wang, Jingxuan Zhang, Xiaobo Wang	17
19	Up-Regulation of PAI-1 and Down-Regulation of uPA Are Involved in Suppression of Invasiveness and Motility of Hepatocellular Carcinoma Cells by a Natural Compound Berberine 2016 ·International Journal of Molecular Sciences ·Xuanbin Wang, Ning Wang, (unknown), Ming Liu, Fengjun Cao, Xianjun Yu, Jingxuan Zhang, Yan Tan, Longchao Xiang, Yibin Feng	34
20	Celastrol Induces Cell Apoptosis and Inhibits the Expression of the AML1-ETO/C-KIT Oncoprotein in t(8;21) Leukemia 2016 ·Molecules ·Xianjun Yu, Xuzhi Ruan, Jingxuan Zhang, Qun Zhao	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact